Q3 FY2026 · ended Sep 30, 2026 · Revenue $18.09B, +4.7% YoY · Filed Nov 4, 2026
Merck & Co., Inc. (MRK) files with the SEC under industry code 2834, Pharmaceutical Preparations. In Q3 of fiscal 2026, the quarter ended Sep 30, 2026, it reported revenue of $18.1 billion and net income of $5.1 billion. Free cash flow was $5.5 billion. As of Sep 30, 2026 it held $11.3 billion in cash and investments and $53.8 billion in total debt.
Revenue
$18.09B
+4.7% vs year-ago quarter
Net income
$5.07B
-12.4% vs year-ago quarter
Operating cash flow
$6.56B
-16.2% vs year-ago quarter
Free cash flow
$5.52B
-19.3% vs year-ago quarter
EPS
$2.04
-12.1% vs year-ago quarter
Dividend per share
$0.85
+4.9% vs year-ago quarter
Shares outstanding
2.47B
-0.7% vs year-ago quarter
Net cash
$-42.55B
Q3 FY2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- MRK (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- NJ
- Headquarters
- Rahway, NJ
- SEC filer status
- Large accelerated filer
- SEC CIK
- 310158
- Former names
- Merck & Co. Inc. (until Dec 9, 2014); SCHERING PLOUGH CORP (until Oct 29, 2009)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
- Pfizer Inc PFE
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $18.1B | $16.6B | $16.3B | $16.4B | $17.3B |
| Net income | $5.1B | -$1.3B | -$4.2B | $3.0B | $5.8B |
| Diluted EPS | $2.04 | -$0.54 | -$1.72 | $1.19 | $2.32 |
| Operating cash flow | $6.6B | $5.4B | $3.9B | $2.9B | $7.8B |
| Free cash flow | $5.5B | $4.5B | $2.9B | $1.8B | $6.8B |
| Total assets | $132.8B | $129.8B | $128.7B | $136.9B | $129.5B |
| Stockholders' equity | $44.9B | $41.9B | $45.9B | $52.6B | $51.9B |
| Cash and investments | $11.3B | $8.4B | $6.8B | $15.5B | $19.3B |
| Total debt | $53.8B | $53.9B | $49.1B | $50.5B | $41.4B |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 4, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Oct 29, 2026 | Oct 29, 2026 |
| 8-K |
Current report
Officer or director change
|
Oct 13, 2026 | Oct 9, 2026 |
| 10-Q | Quarterly report | Aug 7, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 4, 2026 | Aug 4, 2026 |
| 8-K |
Current report
Shareholder vote results
|
May 28, 2026 | May 26, 2026 |
All 1007 Merck & Co., Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.